Preview of an industry panel on RNA therapeutics at a major biopharma convention, focusing on gene therapy approaches for age-related diseases.
Key Takeaways
- Company promotes GF-1002 as a SIRT6 centenarian variant gene therapy candidate
- Proof-of-concept trial in aged dogs started in March 2025, the company reports
- Human clinical trial is planned to test GF-1002 for metabolic steatohepatitis